Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality

Boni Elewski¹
Amir Tavakkol²

¹University of Birmingham in Alabama, Birmingham, AL, USA; ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Abstract: Clinicians now have five oral antifungal therapeutic agents to choose from when assessing the risk–benefits associated with a particular treatment for onychomycosis (OM): griseofulvin, itraconazole, terbinafine, ketoconazole, and fluconazole. Only the first three are approved by the FDA for this indication. Griseofulvin is fungistatic and inhibits nucleic acid synthesis, arresting cell division at metaphase, and impairing fungal wall synthesis. Due to its low cure rates and high relapse, it is rarely used for treatment of onychomycosis. Itraconazole is a broad spectrum drug and is effective against dermatophytes, candida, and some non-dermatophytic molds. Itraconazole works by inhibiting ergosterol synthesis via cytochrome P-450 (CYP450)-dependent demethylation step. This azole antifungal agent is metabolized in the liver by cytochrome P-450 3A4 (CYP3A4), and therefore has the potential to interact with drugs metabolized through this pathway. Terbinafine, an allylamine, is fungicidal and remains at therapeutic levels in keratinized tissues, but with a short plasma half-life of 36 hours. Terbinafine has the advantage in that it does not inhibit CYP3A4 isoenzyme during its metabolism where some 50% of all commonly prescribed drugs are metabolized. The only potentially significant drug interaction with terbinafine is with the cytochrome P-450 2D6 (CYP2D6) isoenzyme. The lack of widely reported or published clinically relevant drug interactions, and extensive experience from a large prospective, surveillance study conducted in “real world” setting with no patient exclusions, suggest that this is not a major issue. The high cure rates of terbinafine against dermatophytes, as shown in many studies since its launch in the 1990s, together with lack of clinically significant drug interactions and well established safety record, indicate the use of continuous oral terbinafine as the top choice for the treatment of onychomycosis in most patients.

Keywords: antifungal, safety, drug interactions, onychomycosis

Introduction
Onychomycosis is relatively common, with a prevalence of 6.5%–6.8% in the general population in Canada (Gupta et al 1997), 8.5% in the general male population in Finland (Heikkila and Stubb 1995), and up to 18.5% in the US (Ghannoum et al 2004). Some studies suggest that as much as 48% of the population may be affected by the age of 70 (Drake et al 1998; Scher 1999).

Balancing patient safety with therapeutic benefit is a prime directive when treating onychomycosis. There are several oral antifungal agents to choose from when assessing the risk–benefits associated with a particular treatment for onychomycosis; griseofulvin, ketoconazole, fluconazole, itraconazole, and terbinafine, although only three have been approved by the Food and Drug Administration (FDA). Fluconazole, anazole much like itraconazole, can be used, but it is not approved for onychomycosis. Ketoconazole is rarely used due to poor tolerability, low efficacy, and the availability
of new antifungal agents. In this review, we compare the mode of action, pharmacokinetics, and potential for drug interactions for various oral antifungal agents. However, the focus is on the mode of action, pharmacokinetics, tolerability, and safety of the three FDA approved oral drugs griseofulvin, itraconazole, and terbinafine. An increased understanding of the metabolism of all the oral antifungal agents allows a better appreciation of potential drug–drug interactions, impact on safety, and appropriate choice of therapy. This is particularly relevant as the number of patients on polypharmacy is increasing due to an aging population and increased comorbidities. Moreover, the widespread use of cholesterol-lowering statins and antihypertensive drugs in otherwise healthy individuals may put many patients at risk for drug interactions.

### Pharmacokinetics

#### Mode of action

Griseofulvin acts by disrupting the fungal mitotic spindle, inhibiting cell wall synthesis, whereas azoles act to block ergosterol synthesis, required for assembly of the fungal cell wall, by inhibiting C14α-demethylase, a member of the cytochrome P-450 (CYP450) family. Terbinafine works much like azoles, with the exception that it blocks ergosterol synthesis further upstream by inhibiting squalene epoxidase. This results in cells becoming deficient in ergosterol and causes accumulation of toxic squalene, which, in turn, results in fungal death. This activity makes terbinafine a fungicidal drug compared with azoles which are fungistatic. This step does not involve CYP450 enzymes, therefore drug interactions are not typically an issue (Figure 1).

#### Absorption

Griseofulvin is poorly absorbed, unless micronized, or coated with polyethylene glycol, or given with fatty meals (Lin et al. 1982). Its absorption decreases with repeated administration, possibly due to damage to the mucosal wall by unabsorbed griseofulvin (Debruyne and Coquerel 2001). This agent has therefore largely been superseded by compounds with better pharmacokinetics. The bioavailability of the most effectiveazole antifungal, itraconazole, is increased by coadministration of food, and decreased in the presence of agents that reduce gastric acidity, eg, antacids, H2 blocker antihistamines, proton pump inhibitors, and the anti-HIV agent, oral didanosine. The efficacy of itraconazole may therefore be compromised by drug coadministration. The bioavailability of terbinafine is good, with 70%–80% of the ingested dose being absorbed.

### Table 1 Characteristics of oral antifungal agents

|                      | Metabolic effect                                      | Route of incorporation into nails            | Oral absorption                                      | Spectrum of activity | Efficacy    |
|----------------------|-------------------------------------------------------|----------------------------------------------|------------------------------------------------------|----------------------|-------------|
| Allylamines (terbinafine) | Accumulation of squalene (fungicidal); depletion of ergosterol (fungistatic) | Via diffusion from nail plate and nail matrix | Good absorption unaffected by food or drug coadministration | Broad                | Very high   |
| Triazoles (itraconazole, fluconazole) | Depletion of ergosterol (fungistatic) | Via diffusion from nail bed and nail matrix | Absorption improved if administered with food; absorption decreased if coadministered with agents that decrease gastric acidity | Broad | Intraconazole more effective than fluconazole |
| Antibiotics (griseofulvin) | Disruption of fungal mitotic spindle (fungicidal) | Deposited in keratin matrix precursor cells | Poorly absorbed but improved if administered with food | Narrow | Low         |
and maximal plasma concentrations reached within 8 hours (Debruyne and Coquerel 2001). In addition, the absorption of terbinafine is unaffected by coadministration of food or agents that decrease gastric pH (Table 1).

Concentrations in the nails and plasma
Steady-state plasma levels of terbinafine are reached after 10–14 days of treatment (De Doncker 1997), and itraconazole within 3 weeks (Leyden 1998). Both terbinafine and itraconazole can be measured in the nail by 7 days after the start of treatment, indicating that the route of entry into the nail plate is via the nail bed and the matrix (De Doncker 1997), rather than solely by incorporation into keratin precursor cells, as seen with griseofulvin (Debruyne and Coquerel 2001). Terbinafine reaches a steady state in the nail after 1 week of treatment, whereas itraconazole may require 3–12 weeks; these levels are then sustained in the nail plate for several months.

The older generation of antifungal drugs (eg, griseofulvin) had to be used continuously until an entirely new nail plate was grown out, which could take up to a year. Griseofulvin has low affinity for keratins and drug levels decline rapidly with plasma levels (Meinhof 1993). Also, the drug persists for only a short duration, for approximately two weeks after treatment is discontinued. On the other hand, both itraconazole and terbinafine are keratinophilic and lipophilic, allowing them to be used for only a short period of time. Terbinafine can persist in the nails between 24 and 156 days (Debruyne and Coquerel 2001); this allows terbinafine to be used effectively with relatively short courses of treatment. Plasma levels of terbinafine and itraconazole fall rapidly after the end of treatment, and the shorter treatment requirements with both drugs further minimize the likelihood of systemic side effects (Debruyne and Coquerel 2001).

Drug interactions
Potential drug interactions that could reduce efficacy or drug toxicity must be taken into account when assessing the benefits and risks of the different oral antifungal agents. The most common hepatic enzyme involved in drug metabolism is cytochrome 3A4 (CYP3A4), which is required for the clearance of many different therapeutic agents.

Griseofulvin
Griseofulvin is not indicated for those with porphyria and hepatocellular failure. Also, patients on warfarin-type anticoagulants may need an adjustment of their anticoagulant dose (Develoux 2001). These may cause contraceptive failure especially of low dose pills. The major drug interactions noted are with phenobarbital, anticoagulants, and oral contraceptives.

Azole antifungal agents
These are metabolized in the liver by CYP3A4, and thus have the potential to interact with a long list of clinically important agents (Table 2). In particular, concurrent administration of azole antifungal agents and the following therapeutics are contraindicated: the antidyshrhythmic and antimalarial agent, quinidine; benzodipines that undergo oxidative metabolism (including alprazolam, chlordiazepoxide, clonazepam, diazepam, estazolam, flurazepam, halazepam, quazepam, and triazolam); doxetilide; the antipsychotic, pimozide; and the statins, lovastatin,

| Table 2 Drug–drug interactions observed with azole antifungal drugs and CYP3A4 metabolizing agents |
|-------------------------------------------------|-------------------------------------------------|
| **Agent**                                      | **Indication**                                  |
| Quinidine                                     | Antimalarial prophylaxis                        |
| Quinidine                                     | Arhythmias                                      |
| Selected benzodiazepines                      | Anxiety                                         |
| Pimozide                                      | Psychotic symptoms                              |
| Dofetilide                                    | Arhythmias                                      |
| Lovastatin, simvastatin, atovastatin          | High cholesterol, heart disease                 |
| Reported drug–drug interactions               |                                                 |
| Nifedipine                                    | Hypertension                                    |
| Potential for drug–drug interactions          |                                                 |
| Phenytoin                                     | Epilepsy                                        |
| Astemizole                                    | Allergy                                         |
| Midazolam                                     | Anxiety                                         |
| Oral contraceptives                           | Contraception                                   |
| Reaglinide, pioglitzone                       | Diabetes                                        |
| Cisapride                                     | Poor gastrointestinal motility                  |
| Didanosine                                    | HIV                                             |
| Ritonavir, saquinavir, amprenavir             | HIV                                             |
| Digoxin                                       | Congestive heart failure                        |
| H2 receptor blockers                          | Dyspepsia, stomach ulcer                       |
| Isoniazid                                     | Tuberculosis                                    |
| Rifampicin                                    | Tuberculosis                                    |
| Tacrolimus                                    | Transplant recipients                           |
| Vincristine                                   | Solid tumors                                    |
| Warfarin                                      | Anticoagulant                                   |

Therapeutics and Clinical Risk Management 2005:1(4)
simvastatin, and atorvastatin (Katz 1999; Shapiro and Shear 2002). Peripheral edema resulting from coadministration of itraconazole and calcium channel blocker, nifedipine, has also been reported (Tailor et al 1996).

Other commonly used agents that are metabolized by CYP3A4 are warfarin, cisapride, and cyclosporine. Monitoring of serum levels, and dosage adjustment if indicated, should therefore be carried out during treatment with itraconazole (Shapiro and Shear 2002). Inhibition of CYP3A4 by itraconazole may increase warfarin’s anticoagulant activity when administered together (Del Rosso 2004). Similarly, some oral antidiabetic agents, including reaglizide and pioglitazone, are metabolized by CYP3A4, and concurrent administration may cause hypoglycemia (Del Rosso 2004). Any agent that induces CYP3A4, such as rifampicin and phenytoin, may increase the metabolism and therefore reduce the efficacy of itraconazole (Shear et al 2000). Itraconazole levels should therefore be monitored in the event of coadministration with these agents.

Azole antifungal agents have also been implicated in several hormone–drug interactions (Venkatakrishnan et al 2000). Patients with HIV infection undergoing treatment with highly active retroviral therapy are also likely to be receiving protease inhibitors such as ritonavir, saquinavir, or amprenavir that are potent inhibitors of CYP3A4. The effects of ketoconazole on amprenavir and saquinavir have been documented, and in the event of concurrent treatment with azole antifungal agents and protease inhibitors, dose reduction of the latter is required.

**Terbinafine (allylamine)**

In contrast with azole antifungal agents, the potential of terbinafine for drug interaction is generally considered low. Side effects associated with CYP3A4 are not observed. While terbinafine is metabolized extensively in the liver, this occurs via the action of various P-450 enzymes (eg, CYP2C9, CYP1A2, CYP3A4, CYP2C8, and CYP2C19) (Vickers et al 1999). In addition, metabolism of terbinafine requires less than 5% of the total liver CYP450 capacity (Vickers et al 1999). Clinically significant drug interactions are limited to cimetidine and rifampicin, which decrease and increase the rate of terbinafine plasma clearance, respectively. The rate of clearance of terbinafine is reduced by one-third in the presence of cimetidine, and doubles in the presence of rifampicin (Shear et al 2000). Terbinafine inhibits the cytochrome family member, cytochrome P-450 2D6 (CYP2D6) (Abdel-Rahman et al 1999), and caution may be indicated when administering CYP2D6 substrates, such as nortriptyline, desipramine, perphenazine, metoprolol, encainide, and propafenone (Shear et al 2000; Debruyne and Coquereul 2001). Concentrations of warfarin may be altered when coadministered with terbinafine (Shear et al 2000).

Terbinafine has a terminal half-life of 16–22 hours (Debruyne and Coquereul 2001). This is prolonged in patients with liver or kidney impairment, and patients with a creatinine clearance less than 50 mL/min or serum creatinine level of more than 300 µmol/L should receive half the normal dose. Terbinafine is primarily excreted (> 70%) in the urine (see Table 3) (Balfour and Faulds 1992).

**Liver enzyme elevations**

Despite transient asymptomatic liver enzyme changes seen in clinical trials, terbinafine is not listed in the British National Formulary as a potential inducer of liver enzymes. While some rare cases of hepatic failure have been reported among millions of adults treated for OM (van ‘t Wout et al 1994; Boldewijn et al 1996; Mallat et al 1997; Shiloah et al 1997; Vivas et al 1997; Gupta et al 1998; Anania and Rabin 2002), many of these patients were elderly and/or had preexisting liver diseases; therefore the causal relationship in many such cases has not been unequivocally determined.

The risk of acute liver injury among 69 830 patients treated with oral antifungal agents was determined in a cohort study in which patients with prior liver disease were excluded (Garcia Rodriguez et al 1999). The incidence rates of acute liver injury were found to be 134.1 per 100 000 person-months; (95% confidence interval [CI]: 36.8, 488.0) for ketoconazole, 10.4 (95% CI: 2.9, 38.1) for itraconazole, and 2.5 (95% CI: 0.4, 13.9) for terbinafine. Ketoconazole was associated with the highest relative risk with 228.0 (95% CI: 33.9, 933.0), when compared with the risk among non-users, followed by itraconazole (relative risk [RR] 17.7; 95% CI: 2.6, 72.6) and terbinafine (RR 4.2; 95% CI: 0.2, 24.9). This cohort study confirms the finding that most case reports of liver injury after administration of oral antifungal agents occur with ketoconazole and itraconazole, and argues against using these agents as initial treatment for uncomplicated fungal infections. While the Rodriguez study (Garcia Rodriguez et al 1999) highlights low incidence of liver injury for terbinafine, the higher rates of hepatotoxicity seen with azole antifungals has adversely affected the perception of terbinafine-induced liver enzyme elevation. The incidence of terbinafine-related hepatobiliary dysfunction in the same studies are even lower at 1 in 45 000–120 000 patients (Hay 1993). To put this finding further into context, the low risk
of hepatic injury observed with terbinafine may be comparable to that seen with paracetamol, a medication widely used for pain relief, and perceived as safe by the general population (Friis and Andreasen 1992; Skorepova 2004).

The risk of hepatotoxicity with terbinafine should not be exaggerated, but should be taken into account, together with any other relevant factors. Patients with chronic or active liver diseases should not be treated with terbinafine, and baseline (pretreatment) liver transaminase testing is recommended. While some physicians continue to monitor liver enzymes during the course of terbinafine treatment, this is no longer recommended by the revised current labeling. After many years of experience with terbinafine, the FDA subsequently removed the LFT monitoring recommendation from the terbinafine label (MedWatch 2001). This is in line with early safety data reported for 1508 patients with toenail onychomycosis, with a mean age of 50 years, and extensive intractable disease, averaging over 11 years in duration (Pollak and Billstein 1997). The incidence of hepatic or biliary disorders was 2.8%, of which the most common was abnormal liver function tests (2.4%). A recent study of 504 patients, in which patients with baseline abnormal liver enzymes were excluded, showed no clinically significant alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation in plasma levels when tested 6 weeks into the treatment (250 mg/day) (Pollak et al 2004). For griseofulvin, there is a clear dosage-dependent association with hepatic toxicity, particularly in patients with prior liver damage (Skorepova 2004).

**Tolerability of oral antifungal (adverse drug events)**

**Griseofulvin**

Availability of newer antifungal agents terbinafine and itraconazole suggest that griseofulvin is no longer the treatment of choice for dermatophyte onychomycosis. Side-effects include nausea and rashes in 8%–15% of patients. In adults, it is contraindicated in pregnancy and the

### Table 3 Randomized trials with terbinafine 250 mg daily

| Trial design | Subject (n) | Treatment duration | Mycological cure rate at study end | Reference |
|--------------|-------------|--------------------|-----------------------------------|-----------|
| Terbinafine 250 mg daily vs placebo | 112 | 3 months | Terbinafine 48% | Placebo 13% | Goodfield et al 1992 |
| | 111 | 3 months | 59% | 9% | Watson et al 1995 |
| | 358 | 3 and 6 months | 70% and 87% | 9% | Drake et al 1997 |
| Terbinafine 250 mg daily vs itraconazole 200 mg daily | 195 | 3 months | Terbinafine 78% | Itraconazole 61% | Brautigam et al 1995 |
| | 372 | 3 months | 73% | 46% | De Backer et al 1998 |
| Continuous terbinafine 250 mg daily vs intermittent itraconazole 400 mg daily (LION Study) | 496 | Terbinafine daily for 3 or 4 months, or itraconazole 1 week in every 4, for 3 or 4 months | Terbinafine 76% (3 months) and 81% (4 months) | Itraconazole 38% (3 months) and 49% (4 months) | Evans and Sigurgeirsson 1999 |
| Terbinafine vs griseofulvin | 195 | 24 weeks terbinafine vs 24 weeks griseofulvin | Terbinafine 81% | Griseofulvin 62% | Hofmann et al 1995 |
| | 180 | 12 weeks | 90% | 64% | Haneke et al 1995 |
| Terbinafine 250 mg daily vs fluconazole 150 mg daily | 137 | 3 months terbinafine vs 3 or 6 months fluconazole | Terbinafine 88% | Fluconazole 51% (3 months) and 49% (6 months) | Havu et al 2000 |

**Abbreviations:** LION, lamisil vs itraconazole in onychomycosis.
manufacturers caution against men fathering children for 6 months after therapy.

**Terbinafine**

Safety data from four large-scale post-marketing surveys investigating safety of terbinafine in actual clinical practice in an uncontrolled setting have been pooled and reported (Hall et al 1997; O'Sullivan 1999). The incidence of adverse events was 10.5%; the majority involved the gastrointestinal system (4.9%) or skin (2.3%); these tended to be mild, transient, and reversible. Terbinafine was considered a “possible” or “probable” cause of only 11 (0.04%) serious adverse events. No drug–drug interactions were reported, even in patients taking oral antidiabetic agents (astemizole, terfenadine, or cimetidine), nor were any previously unrecognized risks identified.

In a post-marketing survey of terbinafine conducted in 1996, involving 10 000 patients, transient taste disturbance was reported by 0.06% of patients (O’Sullivan et al 1996). All patients with taste loss fully recovered the sensation, at an average of 6 weeks (range 2–186 weeks) (O’Sullivan et al 1996). As per terbinafine’s prescribing information, rare incidence of cutaneous abnormalities (eg, Stevens-Johnson syndrome or toxic epidermal necrolysis; Carstens et al 1994; Todd et al 1995) have been reported. Over a period of approximately 15 years, only two instances of longer-term taste disturbance have been reported or reversible taste loss or changes (Beutler et al 1993; Duxbury et al 2000).

The good safety profile has been reported in elderly and diabetic patients in early studies (Nedelman et al 1997; Pollak and Billstein 1997; Smith et al 2000; Elewski and Smith 2001). Good safety results have also been obtained in other special patient populations (Cribier and Bakshi 2004; Gupta et al 2005).

In a study by Pollak and Billstein (1997), comparable numbers of patients received 12, 18, and 24 weeks of 250 mg/day terbinafine. No serious adverse events considered to be related to the study drug were reported, either in the intent to treat population as a whole, in those over 60 years (n = 416), or in those with diabetes (n = 77). The most prevalent adverse event (12.3% of patients) was skin-related, most commonly a skin rash or nail disorder. Gastrointestinal complaints (nausea, diarrhea, dyspepsia, and abdominal pain) were recorded in 11.5% of patients, with 3.9% considered to have a relationship with the study drug. In a group of 30 patients aged over 60 years who received 12 weeks of treatment, no serious adverse events occurred (Smith et al 2000). Use of concomitant medications was widespread, with 93.3% of patients receiving at least one prescription or over-the-counter medication during terbinafine treatment, and 27% receiving medications with known interactions with azole antifungals. Although 16 patients used medications metabolized by CYP2D6, no drug interactions occurred between these agents and terbinafine, and no clinical consequences were seen (Smith et al 2000).

HIV patients are also at increased risk for drug interactions, due to compromised liver function and low white cell count (Elewski and Smith 2001). No drug interactions have been observed during terbinafine treatment of fungal infection (onychomycosis, tinea pedis, tinea cruris, tinea corporis) in 57 patients with HIV infection (Nandwani et al 1996; Herranz et al 1997; Rich et al 2001; Smith et al 2001). Although patient numbers are small, there was no evidence of neutropenia, and no detrimental effect on liver function even in patients with serological evidence of viral hepatitis infection. In a subanalysis of 77 patients with diabetes included in an open-label study, the safety profile did not differ from that observed in the general population (Pollak and Billstein 1997). Similarly, no drug interactions were reported in a post-marketing survey in which 3.2% of the 25 884 patients were diabetic (Hall et al 1997). In addition, control of glucose levels remained unaltered during 12 weeks of terbinafine treatment in 89 patients with diabetes, and no drug interactions or hypoglycemic episodes were seen (Cribier and Bakshi 2004; Gupta et al 2005).

**Itraconazole**

Overall, itraconazole is well tolerated, with adverse effects reported in approximately 3% of patients (Scher 1999). The more common adverse effects are headache and gastrointestinal symptoms such as diarrhea, dyspepsia, abdominal pain, constipation, nausea, and flatulence, and dermatologic symptoms such as rash, pruritus, and urticaria. Acute generalized exanthematic pustulosis is associated with both oral itraconazole and terbinafine and has been rarely reported in the literature (Park et al 1997; Hall and Tate 2000). In most cases, there are nearly complete resolution of the pustular eruption within a few weeks following cessation of drugs and treatment with topical and systemic corticosteroids (Hall and Tate 2000). Liver enzyme elevations, reported in 0.3%–0.5% of patients receiving itraconazole therapy (Gupta and Shear 2000). Also, azoles are potent inhibitors of vitanovir, saquinavir, and abacavir and not recommended for this patient population.
Approximately 26% of diabetic patients have onychomycosis, and, compared with nondiabetics, this patient population is at increased risk of secondary complications, including onychocryptosis, bacterial cellulitis, osteomyelitis, gangrene, or foot ulcers (Elewski and Smith 2001). Effective treatment that does not interact with oral hypoglycemic or cardiovascular agents, or worsen glycemic control, is therefore of high importance. Azole antifungal agents are not desirable under such a setting.

Conclusions

Both direct and historical comparison of griseofulvin with studies of the newer antifungal agents terbinafine and itraconazole suggest that griseofulvin is no longer the treatment of choice for dermatophyte onychomycosis. While itraconazole has been used for years with varying success, its major drawback is the high potential for drug interactions. This is particularly relevant since it is a potent inhibitor of CYP3A4 and cannot be conveniently used with statins, antidiabetics, or antihypertensives.

The potential for drug–drug interactions is low with oral terbinafine, and this agent provides a viable treatment option for elderly, diabetic, and immunocompromised patients with HIV, who are likely to be receiving concomitant medication. Moreover, due to the increasing use of cholesterol lowering statins and antihypertensive drugs, many otherwise healthy individuals may become at risk for drug interactions. Terbinafine does not interact with these classes of drugs.

References

Abdel-Rahman SM, Marcucci K, Boge T, et al. 1999. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos, 27:770–5.
Anania FA, Rabin L. 2002. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med, 112:741–2.
Balfour JA, Faulds D. 1992. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs, 43:259–84.
Beutler M, Hartmann K, Kuhn M, et al. 1993. Taste disorders and terbinafine. BMJ, 307:26.
Bodeiwijn OJ, Ottervanger JP, Mostart CM, et al. 1996. Hepatitis attributed to the use of terbinafine. Ned Tijdschr Geneeskd, 140:669–72.
Brautigam M, Nolting S, Schopf RE, et al. 1995. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ, 311:919–22.
Carstens J, Wendelboe P, Sogaard H, et al. 1994. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol, 74:391–2.
Cribier BJ, Bakshi R. 2004. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with onychomycoses. Br J Dermatol, 150:414–20.
De Backer M, De Vroey C, Lesaffre E, et al. 1998. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol, 38:S57–63.
De Doncker P. 1997. Pharmacokinetics of oral antifungal agents. Dermatol Ther, 3:46–57.
Debruyn D, Coquarel A. 2001. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet, 40:441–72.
Del Rosso JQ. 2004. Oral Antifungals: What you should know about drug interactions. Podiatry Today, 116:61–5.
Develoux M. 2001. Griseofulvin can kill intestinal bacteria whose enzymes help steroid absorption. Ann Dermatol Venereol, 128:1317–25.
Drake LA, Scher RK, Smith EB, et al. 1999. Effect of onychomycosis on quality of life. J Am Acad Dermatol, 38:702–4.
Drake LA, Shear NH, Arlette JP, et al. 1997. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol, 37:740–5.
Duxbury AJ, Oliver RJ, Pemberton MN. 2000. Persistent impairment of taste associated with terbinafine. Br Dent J, 188:295–6.
Elewski B, Smith S. 2001. The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive. Cutis, 68:23–9.
Evans EG, Sigurgeirsson B. 1999. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ, 318:1031–5.
Frisi, H, Andreasen PB. 1992. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med, 232:133–8.
Garcia Rodriguez LA, Duque A, Castellsague J, et al. 1999. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol, 48:847–52.
Ghannoum MA, Chaturvedi V, Espinel-Ingroff A, et al. 2004. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol, 42:2977–9.
Goodfield MJ, Andrew L, Evans EG. 1992. Short term treatment of dermatophyte onychomycosis with terbinafine. Br Med Journal, 304:1151–4.
Gupta AK, del Rosso JQ, Lynde CW, et al. 1998. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol, 23:64–7.
Gupta AK, Jain HC, Lynde CW, et al. 1997. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada–a multicenter survey of 2001 patients. Int J Dermatol, 36:783–7.
Gupta AK, Ryder JE, Tavakkol A. 2005. The use of terbinafine in the treatment of onychomycosis in adults and special patient populations: a review of the evidence. J Drugs Dermatol, 4:299–305.
Gupta AK, Shear NH. 2000. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety, 22:1–52.
Hall AP, Tate B. 2000. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australasian J Dermatol, 41:42–5.
Hall M, Monka C, Krupp P, et al. 1997. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol, 133:1213–19.
Hanek E, Tausch I, Brautigam M, et al. 1995. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. J Am Acad Dermatol, 32:72–7.
Havu V, Heikila H, Kuokkanen K, et al. 2000. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamistil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol, 142:97–102.
Hay RJ. 1993. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol, 29:S50–4.
Heikkila H, Stubb S. 1995. The prevalence of onychomycosis in Finland. *Br J Dermatol*, 133:699–703.

Herranz P, Garcia J, De Lucas R, et al. 1997. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. *Br J Dermatol*, 137:577–80.

Hofmann H, Brautigam M, Weidinger G, et al. 1995. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. *Arch Dermatol*, 131:919–22.

Katz HI. 1999. Drug interactions of the newer oral antifungal agents. *Br J Dermatol*, 141:26–32.

Leyden J. 1998. Pharmacokinetics and pharmacology of terbinafine and itraconazole. *J Am Acad Dermatol*, 38:S42–47.

Lin C, Lim J, DiGiore C, et al. 1982. Comparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in man. *J Int Med Res*, 10:274–7.

Mallat A, Zafrani ES, Metreau JM, et al. 1997. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. *Dig Dis Sci*, 42:1486–8.

Medwatch. 2001. Summary Of Safety-Related Drug Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER). Washington, DC, USA; Food and Drug Administration.

Meinhof W. 1993. Kinetics and spectrum of activity of oral antifungals; the therapeutic implications. *J Am Acad Dermatol*, 29:S37–41.

Nandwani R, Parnell A, Youle M, et al. 1996. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. *Br J Dermatol*, 134:22–4.

Pollak RA, Harkless LB, Jennings MB, et al. 2004. Terbinafine: Reality versus perception concerning liver function. *Am Podiatric Med Assoc*, International Annual Meeting, August 2004, Boston, USA.

Pollak RA, Houpert KR, LaMarca A, et al. 2001. Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. *Cuta*, 68:15–22.

Rich P, Houpert KR, LaMarca A, et al. 2001. Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. *Cuta*, 68:15–22.

Scher RK. 1999. Onychomycosis: therapeutic update. *J Am Acad Dermatol*, 40:521–6.

Shapiro LE, Shear NH. 2002. Drug interactions: Proteins, pumps, and P-450s. *J Am Acad Dermatol*, 47:467–84, quiz 485–8.

Shear N, Drake L, Gupta AK, et al. 2000. The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. *Dermatology*, 201:196–203.

Shiloah E, Horowiz M, Zecler E. 1997. Terbinafine-induced cholestatic liver injury. *Harefuah*, 133:11–12, 80–1.

Skorepova M. 2004. Risk of liver damage casued by modern systemic antymycotics. *Ces-iov Derm*, 79:59–61.

Smith EB, Stein LF, Fivenson DP, et al. 2000. The safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. *Int J Dermatol*, 39:859–64.

Smith S, Houpert K, Rich P, et al. 2001. Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients. *Cuta*, 68:30–9.

Todd P, Halpern S, Munro DD. 1995. Oral terbinafine and erythema multiforme. *Clin Exp Dermatol*, 20:247–8.

van ‘t Wout JW, Herrmann WA, de Vries RA, et al. 1994. Terbinafine-associated hepatic injury. *J Hepatol*, 21:115–17.

Venkatarkishan K, von Moltke LL, Greenblatt DJ. 2000. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. *Clin Pharmacokinet*, 38:111–80.

Vickers AE, Sinclair JR, Zollinger M, et al. 1999. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. *Drug Metab Dispos*, 27:1029–38.

Vivas S, Rodriguez M, Palacio MA, et al. 1997. Acute hepatitis associated with terbinafine. *Gastroenterol Hepatol*, 20:456–8.

Watson A, Marley J, Ellis D, et al. 1995. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. *J Am Acad Dermatol*, 33:775–9.